**EVALUATION OF FIBROBLAST GROWTH FACTOR 23 (FGF23) IN SERUM OF PATIENTS WITH DIABETIC NEPHROPATHY**

**Anas Hameed Mezher Mezher**

**Department of Chemistry, Faculty of Science, Cankiri Karatekin University, 18100 Cankırı,Türkiye**

**Sevki Adem**

**Department of Chemistry, Faculty of Science, Cankiri Karatekin University, 18100 Cankırı, Türkiye**

|  |
| --- |
| **ABSTRACT (Times New Roman 12-Bold)**FGF23 is the phosphate-regulating bone-derived hormone and the metabolism of vitamin D3. fgf23 is secreted by osteocytes/osteoblasts and works by binding to the klotho complex of the FGF receptor fgf23 suppresses proximal tubular phosphate reabsorption by reducing sodium phosphate absorption by modulating vitamin D3 expression Metabolizing enzymes and reducing the level of excessive and deficient action of FGF23 at 1.25 dihydroxy vitamin D3 cause hypophosphatemic and hyperphosphatemic disease and FGF23 plays an important role in the development of mineral chronic kidney disease and the identification of FGF23 produced a new concept that bone also functions as an endocrine organ disorderAim of the study to analyze the relationship between vitamin D3 growth factor 23(FGF23) and to evaluate whether these results will be markers for patients with diabetic nephropathyAll groups are between ( 20 -60) years old. The presented study was conduction in the medical city hospital in Baghdad, Iraq. This study included three groups all of them totaling 180 samples and they are first of all 1- the 60 patients with diabetic nephropathy including 30 males and 30 females 2-the 60 patients with kidney disease without diabetes of whom 30 are males and 30 females 3-the healthy(control) 60 of them were 30 males and 30 females.Results showed that is an inverse relationship between vitamin D3 and FGF23 and all there are significant differences except for no difference between age and BMI.  |

# Keywords: *FGF23(fibroblast growth factor 23), Vitamin D3*